Pharmacokinetics/pharmacodynamics of systemically administered polymyxin B against Klebsiella pneumoniae in mouse thigh and lung infection models-Reference-Cited by-同舟云学术

Pharmacokinetics/pharmacodynamics of systemically administered polymyxin B against Klebsiella pneumoniae in mouse thigh and lung infection models

Published:2017-11-14 Issue:2 Volume:73 Page:462-468
ISSN:0305-7453
Container-title:Journal of Antimicrobial Chemotherapy
language:en
Short-container-title:

Author:

Landersdorfer Cornelia B¹²³,Wang Jiping¹,Wirth Veronika¹,Chen Ke¹,Kaye Keith S⁴,Tsuji Brian T³⁵,Li Jian¹⁶,Nation Roger L¹

Affiliation:

1. Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia

2. Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia

3. School of Pharmacy and Pharmaceutical Sciences, University at Buffalo State University of New York, Buffalo, NY, USA

4. Department of Medicine, University of Michigan Medical School, Ann Arbor, MI, USA

5. Laboratory for Antimicrobial Pharmacodynamics, NYS Centre of Excellence in Bioinformatics & Life Sciences, Buffalo, NY, USA

6. Monash Biomedicine Discovery Institute, Department of Microbiology, Monash University, Clayton, Victoria, Australia

Funder

NIH

National Institute of Allergy and Infectious Diseases

NHMRC

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology,Microbiology (medical)

Link

http://academic.oup.com/jac/article-pdf/73/2/462/24332581/dkx409.pdf

Reference36 articles.

1. Colistin and polymyxin B: peas in a pod, or chalk and cheese?;Nation;Clin Infect Dis,2014

2. Differences in potency and categorical agreement between colistin and polymyxin B when testing 15,377 clinical strains collected worldwide;Sader;Diagn Microbiol Infect Dis,2015

3. Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus;Nation;Lancet Infect Dis,2015

4. Pharmacokinetic/pharmacodynamic investigation of colistin against Pseudomonas aeruginosa using an in vitro model;Bergen;Antimicrob Agents Chemother,2010

5. New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection;Cheah;J Antimicrob Chemother,2015

Cited by 93 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outcome of intravenous and inhaled polymyxin B treatment in patients with multidrug-resistant gram-negative bacterial pneumonia;International Journal of Antimicrobial Agents;2024-10

2. Polymyxin B Plus Aerosolized Colistin vs Polymyxin B Alone in Hospital-acquired Pneumonia (“AEROCOL” Study): A Feasibility Study;Indian Journal of Critical Care Medicine;2024-07-31

3. Three methods to optimise polymyxin B dosing using estimated AUC after first dose: validation with the data generated by Monte Carlo simulation;Xenobiotica;2024-07-08

4. Efficacy and Safety Factors Related to Plasma Concentration-Optimized Polymyxin B Therapy in Treating Carbapenem-Resistant Gram-Negative Bacterial Infections in China;Infection and Drug Resistance;2024-07

5. Modelling lung infection with Klebsiella pneumoniae after murine traumatic brain injury;Journal of Neuroinflammation;2024-05-08